The Asia Pacific Immune Checkpoint Inhibitors Market would witness market growth of 16.9% CAGR during the forecast period (2021-2027).
Immune checkpoints are important immune system regulators that help preserve self-tolerance, avoid autoimmune reactions, and reduce tissue damage by controlling the duration and severity of immune responses. In addition, immunological checkpoints are frequently abundantly expressed in cancer cells or noninvasive cells in tumor tissues. Checkpoint molecules have been explored as prospective therapeutic targets for the treatment of different types of malignancies based on extensive physiological investigations as well as preclinical and clinical trials.
The very first immune checkpoint inhibitors across the market were ipilimumab and Yervoy. Several anti-PD-1 and anti-PD-L1 antibodies have been created in response to the encouraging outcomes of Yervoy. Although other checkpoints, such as LAG-3 and TIM-3, have been explored, the only immune checkpoint inhibitors that have been licensed are CTLA-4, PD-1, and PD-L1.
Asia Pacific is undergoing constant developments in the healthcare sector. With the ongoing advancements, countries across the region are determined to establish a robust healthcare infrastructure for the treatment of various prevailing diseases. In addition, stomach cancer is one of the most common disorders across the region. The substantial existence of stomach cancer across the region is the consumption of salty and smoky edibles.
Moreover, according to the National Library of Medicine, in APAC, stomach cancer is the third most frequent cancer and the second leading cause of death from cancer. Eastern Asia has the highest incidence rates, while other sections of APAC have varying rates. Although mortality rates are gradually decreasing, they remain a significant public health issue.
The China market dominated the Asia Pacific Immune Checkpoint Inhibitors Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $3,563.5 million by 2027. The Japan market is estimated to grow at a CAGR of 16.2% during (2021 - 2027). Additionally, The India market would exhibit a CAGR of 17.6% during (2021 - 2027).
Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Immune Checkpoint Inhibitors Market is Projected to reach USD 75.9 Billion by 2027, at a CAGR of 16.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By Type
- PD-1 Inhibitor
- PD-L1 Inhibitor
- CTLA-4 Inhibitor
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Beigene Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Merck Group (Merck Sharp & Dohme Corp.)
- Sanofi S.A.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Immune Checkpoint Inhibitors Market, by Application
1.4.2 Asia Pacific Immune Checkpoint Inhibitors Market, by Type
1.4.3 Asia Pacific Immune Checkpoint Inhibitors Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
Chapter 4. Asia Pacific Immune Checkpoint Inhibitors Market by Application
4.1 Asia Pacific Lung Cancer Market by Country
4.2 Asia Pacific Bladder Cancer Market by Country
4.3 Asia Pacific Melanoma Market by Country
4.4 Asia Pacific Hodgkin lymphoma Market by Country
4.5 Asia Pacific Other Application Market by Country
Chapter 5. Asia Pacific Immune Checkpoint Inhibitors Market by Type
5.1 Asia Pacific PD-1 Inhibitor Market by Country
5.2 Asia Pacific PD-L1 Inhibitor Market by Country
5.3 Asia Pacific CTLA-4 Inhibitor Market by Country
Chapter 6. Asia Pacific Immune Checkpoint Inhibitors Market by Country
6.1 China Immune Checkpoint Inhibitors Market
6.1.1 China Immune Checkpoint Inhibitors Market by Application
6.1.2 China Immune Checkpoint Inhibitors Market by Type
6.2 Japan Immune Checkpoint Inhibitors Market
6.2.1 Japan Immune Checkpoint Inhibitors Market by Application
6.2.2 Japan Immune Checkpoint Inhibitors Market by Type
6.3 India Immune Checkpoint Inhibitors Market
6.3.1 India Immune Checkpoint Inhibitors Market by Application
6.3.2 India Immune Checkpoint Inhibitors Market by Type
6.4 South Korea Immune Checkpoint Inhibitors Market
6.4.1 South Korea Immune Checkpoint Inhibitors Market by Application
6.4.2 South Korea Immune Checkpoint Inhibitors Market by Type
6.5 Singapore Immune Checkpoint Inhibitors Market
6.5.1 Singapore Immune Checkpoint Inhibitors Market by Application
6.5.2 Singapore Immune Checkpoint Inhibitors Market by Type
6.6 Malaysia Immune Checkpoint Inhibitors Market
6.6.1 Malaysia Immune Checkpoint Inhibitors Market by Application
6.6.2 Malaysia Immune Checkpoint Inhibitors Market by Type
6.7 Rest of Asia Pacific Immune Checkpoint Inhibitors Market
6.7.1 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Application
6.7.2 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Type
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Beigene Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Shanghai Junshi Biosciences Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Eli Lilly and Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Merck Group (Merck Sharp & Dohme Corp.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Sanofi S.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.8.5.3 Acquisition and Mergers:
7.9 Merck & Co., Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. F. Hoffmann-La Roche Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations and Agreements:
7.10.5.2 Approvals and Trials:
TABLE 1 Asia Pacific Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 2 Asia Pacific Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Immune Checkpoint Inhibitors Market
TABLE 4 Acquisition and Mergers– Immune Checkpoint Inhibitors Market
TABLE 5 Approvals and Trials– Immune Checkpoint Inhibitors Market
TABLE 6 Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 7 Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 8 Asia Pacific Lung Cancer Market by Country, 2017 - 2020, USD Million
TABLE 9 Asia Pacific Lung Cancer Market by Country, 2021 - 2027, USD Million
TABLE 10 Asia Pacific Bladder Cancer Market by Country, 2017 - 2020, USD Million
TABLE 11 Asia Pacific Bladder Cancer Market by Country, 2021 - 2027, USD Million
TABLE 12 Asia Pacific Melanoma Market by Country, 2017 - 2020, USD Million
TABLE 13 Asia Pacific Melanoma Market by Country, 2021 - 2027, USD Million
TABLE 14 Asia Pacific Hodgkin lymphoma Market by Country, 2017 - 2020, USD Million
TABLE 15 Asia Pacific Hodgkin lymphoma Market by Country, 2021 - 2027, USD Million
TABLE 16 Asia Pacific Other Application Market by Country, 2017 - 2020, USD Million
TABLE 17 Asia Pacific Other Application Market by Country, 2021 - 2027, USD Million
TABLE 18 Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 19 Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 20 Asia Pacific PD-1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 21 Asia Pacific PD-1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 22 Asia Pacific PD-L1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 23 Asia Pacific PD-L1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 24 Asia Pacific CTLA-4 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 25 Asia Pacific CTLA-4 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 26 Asia Pacific Immune Checkpoint Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 27 Asia Pacific Immune Checkpoint Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 28 China Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 29 China Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 30 China Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 31 China Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 32 China Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 33 China Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 34 Japan Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 35 Japan Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 36 Japan Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 37 Japan Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 38 Japan Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 39 Japan Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 40 India Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 41 India Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 42 India Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 43 India Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 44 India Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 45 India Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 46 South Korea Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 47 South Korea Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 48 South Korea Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 49 South Korea Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 50 South Korea Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 51 South Korea Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 52 Singapore Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 53 Singapore Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 54 Singapore Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 55 Singapore Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 56 Singapore Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 57 Singapore Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 58 Malaysia Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 59 Malaysia Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 60 Malaysia Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 61 Malaysia Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 62 Malaysia Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 63 Malaysia Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 64 Rest of Asia Pacific Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 65 Rest of Asia Pacific Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 66 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 67 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 68 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 69 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 70 KEY INFORMATION – ASTRAZENECA PLC
TABLE 71 KEY INFORMATION – BEIGENE LTD.
TABLE 72 KEY INFORMATION – SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
TABLE 73 KEY INFORMATION – BRISTOL MYERS SQUIBB COMPANY
TABLE 74 KEY INFORMATION – GLAXOSMITHKLINE PLC
TABLE 75 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 76 KEY INFORMATION – MERCK GROUP
TABLE 77 KEY INFORMATION – SANOFI S.A.
TABLE 78 KEY INFORMATION - MERCK & CO., INC.
TABLE 79 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: Sanofi s.a.